Prediction of improved survival in patients with pancreatic cancer via IL-21 enhanced detection of mesothelin epitope-reactive T-cell responses

Most patients with pancreatic cancer present with extensive metastasis at diagnosis, with a 5-year survival rate of approximately 5%, despite chemotherapy and surgery. New treatment modalities are needed to improve survival. Mesothelin is a tumor-associated antigen (TAA) in patients with pancreatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Qingda, Valentini, Davide, Rao, Martin, Liu, Zhenjiang, Xie, Shanshan, Morgell, Ann, Dodoo, Ernest, Löhr, Matthias, Rangelova, Elena, del Chiaro, Marco, Ernberg, Ingemar, Maeurer, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976477/
https://www.ncbi.nlm.nih.gov/pubmed/29854291
http://dx.doi.org/10.18632/oncotarget.25121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976477/
https://www.ncbi.nlm.nih.gov/pubmed/29854291
http://dx.doi.org/10.18632/oncotarget.25121

Ejemplares similares